Menu
Platform Technologies
Brain Disease
Cancer Therapy
NTT-003 (Eyedrop Formulation for Wet-AMD)
Summary
NTT-003 is an eye drop nanoformulation of axitinib-loaded mesoporous silica nanoparticles (MSNs) developed for the treatment of wet age-related macular degeneration (wet-AMD). This formulation enables efficient delivery of axitinib across the blood-ocular barrier to the posterior segment of the eye following topical administration, offering a non-invasive alternative to intravitreal injection.
Pharmacokinetics and Ocular Distribution
NTT-003 reaches the posterior segment of the eye (retina, choroid, and sclera) and remains for several hours before being cleared within 24 hours, as demonstrated in both rodent and non-rodent studies.
Efficacy in Wet-AMD
• NTT-003 demonstrated superior anti-neovascularization efficacy compared to the commercial intravitreal drug Eylea in animal models of wet-AMD.
• No acute eye irritation or corrosion was observed with either NTT-003 or MSN alone.